Ceftriaxone
- Generic Name
- Ceftriaxone
- Brand Names
- Rocephin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18N8O7S3
- CAS Number
- 73384-59-5
- Unique Ingredient Identifier
- 75J73V1629
- Background
Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S...
- Indication
Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabil...
- Associated Conditions
- Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial
- Associated Therapies
- -
Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection
- Conditions
- Interventions
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Assistance Publique - Hรดpitaux de Paris
- Target Recruit Count
- 274
- Registration Number
- NCT02424461
- Locations
- ๐ซ๐ท
Saint Louis hospital, Paris, France
A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 86
- Registration Number
- NCT02384200
- Locations
- ๐บ๐ธ
Mayo Clinic in Arizona, Phoenix, Arizona, United States
๐บ๐ธUCSD Medical Center, San Diego, California, United States
๐บ๐ธThe Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital
- Conditions
- Interventions
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 190
- Registration Number
- NCT02334124
- Locations
- ๐ฆ๐บ
The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2017-03-22
- Target Recruit Count
- 180
- Registration Number
- NCT02257918
- Locations
- ๐บ๐ธ
Indiana University - Bell Flower Clinic, Indianapolis, Indiana, United States
๐บ๐ธDurham County Health Department, Durham, North Carolina, United States
๐บ๐ธPublic Health STD Clinic, Seattle, Washington, United States
Typhoid Fever: Combined vs. Single Antibiotic Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT02224040
- Locations
- ๐ณ๐ต
Dhulikhel hospital, Dhulikhel, Nepal
Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea
- Conditions
- Interventions
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT02210325
Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Kangbuk Samsung Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT02098486
- Locations
- ๐ฐ๐ท
Sungkyunkwan University Kangbuk Samsung Hospital, Seoul, Korea, Republic of
Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT02015637
- Locations
- ๐บ๐ธ
Melinta 304 Study, Erie, Pennsylvania, United States
๐บ๐ธMelinta 304 Study Site, Seattle, Washington, United States
Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 100
- Registration Number
- NCT01757236
- Locations
- ๐ซ๐ท
CHRU de Tours, Tours, Indre et Loire, France
๐ฎ๐นAzienda Opedaliera Universitaria San Maria della Misericordia, Udine, Italy
๐ซ๐ทCHU de Nantes, Nantes, France
Antibiotics for Klebsiella Liver Abscess Study
- Conditions
- Interventions
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 152
- Registration Number
- NCT01723150
- Locations
- ๐ธ๐ฌ
National University Hospital, Singapore, Singapore
๐ธ๐ฌSingapore General Hospital, Singapore, Singapore
๐ธ๐ฌTan Tock Seng Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.